SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab

SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab

Objectives: In this early retrospective cohort study, a total of 26 patients with SARS-CoV-2 were treated with bamlanivimab or casirivimab/imdevimab, and the reduction of the viral load associated with the developed clinical symptoms was analyzed. Methods: Patients in the intervention groups receive...

Full description

Bibliographic Details
Main Authors: Martin Heller, Clara Henrici, Judith Büttner, Sebastian Leube, Isabelle Treske, Petra Pospischil, Michael Doll, Ilka Schanz, Agnes Hallier, Eva Herrmann, Michael Schmidt, Christoph Sarrazin
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:International Journal of Infectious Diseases
Subjects:
COVID-19
Bamlanivimab
Casirivimab
Imdevimab
Antibody therapy
Viral load
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971223000127

Internet

http://www.sciencedirect.com/science/article/pii/S1201971223000127

Similar Items